NCT00391976View on ClinicalTrials.gov

Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis

PHASE3CompletedINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Cystic Fibrosis

Interventions

DRUG

Tobramycin solution for inhalation 300 mg

Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.